|
 | Up a level |
Zaitceva, V, Tan, I, Mills, M. and Kanavos, P. 
ORCID: 0000-0001-9518-3089
(2024)
HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA.
Value in Health, 27 (12, Supplement).
S323 - S323.
ISSN 1098-3015
Eaves, K., Lin, R., Alani, A. H. ORCID: 0000-0001-6318-3017, Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
HTA117 Sentiment analysis of clinical evaluations in HTA: evidence from Canada, England, Scotland, Sweden, France, and Germany.
Value in Health, 27 (12, Supplement).
S376 - S376.
ISSN 1098-3015
Civitelli, D. ORCID: 0009-0002-9398-8857, Politopoulou, K., Mills, Mackenzie and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs.
Value in Health, 27 (12, Supplement).
S356 - S356.
ISSN 1098-3015
Lin, R., Eaves, K., Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
HTA64 Leveraging machine learning for predicting health technology assessment outcomes.
Value in Health, 27 (12, Supplement).
S365 - S365.
ISSN 1098-3015
Chavez, D., Tolkmitt, F., Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process.
Value in Health, 27 (12, Supplement).
S323 - S323.
ISSN 1098-3015
